Biological specimen collection

OTHER2 trials

Sponsors

New Mexico Cancer Research Alliance, Case Comprehensive Cancer Center

Conditions

CancerCancer RiskSomatic Mutation

Unknown Phase

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

RecruitingNCT03977402

New Mexico Cancer Research AllianceCancer, Cancer Risk

Start: 2016-01-27End: 2037-12-31Target: 47500Updated: 2025-05-22

Linking Somatic Mutation Rate With Baseline Exposure in East Palestine

RecruitingNCT06357845

Case Comprehensive Cancer CenterSomatic Mutation

Start: 2024-08-16End: 2026-09-30Target: 500Updated: 2026-03-16

Related Papers

Abstract 63: Intratumoral <i>Candida albicans</i> associates with hypoxia and poor outcomes in non small cell lung cancer (NSCLC).

Cancer Research2026-04-03

Abstract B020: Unveiling the tumor-associated microbiome in ovarian cancer: Correlations with clinical features, outcomes, and treatment strategies

Cancer Research2025-09-19

Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

Cells2024-12-032 citations

Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers.

2024-06-101 citations

A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.

Journal of Clinical Oncology2024-06-01

Abstract 3886: Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines

Cancer Research2024-03-22

Abstract 71: Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy

Cancer Research2024-03-22

898 Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma

Regular and Young Investigator Award Abstracts2023-10-31

151 Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines

Regular and Young Investigator Award Abstracts2023-10-31

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

Regular and Young Investigator Award Abstracts2023-10-31

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Cancers2023-10-1010 citations

Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.

Journal of Clinical Oncology2023-06-012 citations

1147 Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers

Regular and Young Investigator Award Abstracts2022-11-011 citations

1279 A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study

Regular and Young Investigator Award Abstracts2022-11-01

54 Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors

Regular and Young Investigator Award Abstracts2022-11-01